In agreement with these Hsp90/Cdc37 inhibitor characteristics, elaiophylin treatment of KRAS-G13D mutant MDA-MB-231 triple negative breast cancer cells (Figure 2A) or KRAS-G12C mutant MIA PaCa-2 pancreatic cancer cells (Figure 2B) led to a dose-dependent decrease of kinases C-Raf, Akt, and ERK1/2, while Hsp70 or Hsp90 were not induced. The gene discussed is KRAS; the disease is pancreatic neoplasm.